25. Progressive multifocal leukoencephalopathy Disease details / Clinical trials / Drug dev / DR info
Clinical trials : 26 / Drugs : 35 - (DrugBank : 22) / Drug target genes : 8 - Drug target pathways : 37
Progressive multifocal leukoencephalopathy and other diseases between which drug repositioning (DR) might occur (Sakate and Kimura 2021) . Circle size: Number of drugs, Line breadth: Score (Drug repositionability)
ID | Diseases (Sorted by score) | Score |
---|---|---|
25 | Progressive multifocal leukoencephalopathy | - |
13 | Multiple sclerosis/Neuromyelitis optica | 7.000 |
46 | Malignant rheumatoid arthritis | 7.000 |
26 | HTLV-1-associated myelopathy | 5.278 |
49 | Systemic lupus erythematosus | 5.188 |
96 | Crohn disease | 5.173 |
97 | Ulcerative colitis | 3.621 |
28 | Systemic amyloidosis | 2.390 |
40 | Takayasu arteritis | 1.491 |
285 | Fanconi anemia | 1.457 |
41 | Giant cell arteritis | 1.442 |
56 | Behcet disease | 1.429 |
11 | Myasthenia gravis | 1.400 |
53 | Sjogren syndrome | 1.379 |
34 | Neurofibromatosis | 1.345 |
85 | Idiopathic interstitial pneumonia | 1.338 |
51 | Scleroderma | 1.331 |
16 | Crow-Fukase syndrome | 1.143 |
220 | Rapidly progressive glomerulonephritis | 1.000 |
30 | Distal myopathy | 1.000 |